Aprotinin Adverse Events: What the Label and Studies Report

Aprotinin at a glance

Aprotinin is a prescription medicine, not a product that reaches a patient outside clinical supervision. It is a polypeptide serine protease inhibitor given intravenously, and it is administered by specialists in a controlled clinical setting: hospital operating rooms, infusion areas and critical care units, with monitoring staff and resuscitation equipment on hand. Where the product has been marketed, approved indications have been limited at label level to reducing blood loss and transfusion requirement in defined cardiac surgery populations. Any other application, including the surgical and bleeding settings explored in the literature below, is investigational. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing specialist team about any medicine, symptom or treatment decision.

Published reviews placed aprotinin among the antifibrinolytic and plasmin inhibiting agents used to limit surgical bleeding, and a 2014 review of plasmin inhibitors for fibrinolysis related disorders described how that drug class was developed and studied (PMID 24659483). A 2001 survey of technologies used to reduce allogeneic blood transfusion in the United States reported how widely such blood conservation measures were adopted across hospitals (PMID 11299024).

Boxed warning: what the label carries

The United States labeling for the brand aprotinin product carried a boxed warning concerning anaphylactic and anaphylactoid reactions, including reactions that were fatal. Key points the boxed warning conveyed, as a matter of label content rather than as guidance to any reader:

• Hypersensitivity reactions could occur with any exposure, including a first exposure.
• Risk was described as substantially higher with re-exposure, and particularly higher when re-exposure occurred within a limited interval after a previous dose.
• Labeling described a test dose step performed by the clinical team before the full dose, and directed that the drug be given only where facilities for immediate treatment of severe reactions, including cardiopulmonary bypass where relevant, were available.
• Labeling instructed that exposure history be established before use.

No administration, reconstitution or dosing details appear on this page. Those belong to the labeling held by the treating specialist team and to the clinicians who prescribe and administer the medicine.

Serious adverse reactions: what studies report

Hypersensitivity and anaphylaxis

Hypersensitivity has been the most prominent safety theme attached to aprotinin in both labeling and review literature. A 2006 review of aprotinin in cardiac surgery examined the agent's clinical role in reducing blood loss alongside the safety questions that surrounded it (PMID 16509811). A 2004 review of the spine surgery literature similarly collected published reports of aprotinin use in that operative setting and summarised what investigators had reported about bleeding, transfusion and tolerability (PMID 15239557); spine surgery use was investigational rather than an approved indication.

Reactions described in labeling ranged from cutaneous signs such as flushing, urticaria and rash through to bronchospasm, hypotension, circulatory collapse and cardiac arrest. Labeling characterised severe reactions as uncommon in absolute terms but potentially abrupt in onset, and tied risk to prior exposure history. Because the reaction can begin during the infusion, the clinical team monitors directly; a patient or family member noticing a symptom in hospital raises it with the staff present.

Renal effects

Renal dysfunction has been the second recurring safety signal in the aprotinin literature. Labeling listed renal impairment and increases in serum creatinine among adverse reactions observed in cardiac surgery populations, with the caution that perioperative renal injury has many contributors beyond any single drug. A 2014 review of adjunct agents for bleeding placed antifibrinolytic drugs in context and discussed how their benefits on blood loss were weighed against reported safety concerns (PMID 25159711). A 2015 clinical review of tranexamic acid described that agent's pharmacology and clinical use as an antifibrinolytic alternative within the same therapeutic space (PMID 25797505).

Cardiovascular, thrombotic and mortality signals

Labeling and the review literature described myocardial infarction, graft occlusion, cerebrovascular events and other thrombotic events among serious adverse reactions reported in surgical populations receiving aprotinin, again within a setting where baseline event rates are already high. Concerns about cardiovascular outcomes and mortality were central to the regulatory history of the product. A 2026 commentary on shrinking pharmacological options in modern anaesthesia discussed how agents have been withdrawn or restricted and what that has meant for anaesthetic practice (PMID 42106242). Marketing status for aprotinin has differed by country and has changed over time, with restricted indications in some jurisdictions; the current national labeling and the specialist team are the authority on availability and on which patients a product is licensed for.

Warnings and precautions the label lists

• Prior exposure. Labeling directed that previous aprotinin exposure be identified, since re-exposure carried the highest hypersensitivity risk.
• Setting of administration. Labeling restricted use to settings with immediate resuscitation capability.
• Renal monitoring. Labeling flagged renal function assessment in the perioperative period.
• Coagulation test interference. Aprotinin affects activated clotting time measurements, which labeling addressed because heparin management during bypass relies on those tests.
• Fibrin sealant preparations. Aprotinin also appears as a component of some surgical sealants, a different exposure route with its own labeling.
• Pregnancy, lactation, paediatric and geriatric use. Labeling carried the usual special population sections, with limited data in several of them.

Common adverse reactions: what studies report

In controlled cardiac surgery trials summarised in labeling, many reported adverse events were common to major surgery itself: atrial fibrillation and other arrhythmias, hypotension, fever, nausea, anaemia, pleural effusion, respiratory complications and infection. Labeling generally presented event rates alongside placebo or comparator rates for that reason, and frequency figures therefore reflect a surgical population rather than a healthy one. The 2006 cardiac surgery review discussed this interpretive problem when weighing reported benefits against reported harms (PMID 16509811).

Reported events grouped by body system

Study types and populations behind these reports

Most of what has been published about aprotinin tolerability came from randomised trials and observational series in adult cardiac surgery, where the drug's approved indication sat, plus review articles that pooled and interpreted that body of work. The 2006 cardiac surgery review was a narrative expert review rather than a meta-analysis (PMID 16509811), and the 2004 spine surgery paper was a review of published literature in a non cardiac surgical population (PMID 15239557). Investigational use has been explored in other surgical contexts as well; a 2014 meta-analysis examined pharmacological interventions studied for colonic anastomotic healing, illustrating how perioperative drug effects are assessed in abdominal surgery (PMID 25253969).

Several practical limits apply when reading frequency figures. Surgical populations carry high baseline rates of the same events counted as adverse reactions. Trial sizes were often too small to detect uncommon outcomes such as severe anaphylaxis. Comparator choice matters, since aprotinin has frequently been compared with lysine analogue antifibrinolytics rather than placebo, and the 2015 tranexamic acid review described that comparator class in clinical use (PMID 25797505). Reporting standards also changed across decades of publication, which affects how directly older and newer datasets can be compared.

Where questions belong

Aprotinin is given by a specialist team, so every question about whether it is being used, what alternatives exist, what a laboratory value means or what a symptom after surgery represents goes to the prescribing clinician and the hospital team involved in that care. Reasonable questions to raise with a prescriber include prior exposure history, how hypersensitivity risk is handled locally, how renal function is tracked around the procedure, and which antifibrinolytic options the institution uses. Nothing here is a substitute for that conversation, and nothing here describes how the medicine is prepared or given.

References

• Aprotinin in cardiac surgery (Expert Review of Cardiovascular Therapy, 2006)
• Aprotinin in spine surgery: review of the literature (Orthopedics, 2004)
• Adjunct agents for bleeding (Current Opinion in Hematology, 2014)
• Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders (Medicinal Research Reviews, 2014)
• Tranexamic acid: a clinical review (Anaesthesiology Intensive Therapy, 2015)
• Utilization of technologies to reduce allogeneic blood transfusion in the United States (Transfusion Medicine, 2001)
• Shrinking pharmacological options in modern anaesthesia (British Journal of Anaesthesia, 2026)
• Pharmacological interventions for improved colonic anastomotic healing: a meta-analysis (World Journal of Gastroenterology, 2014)